ClinicalTrials.gg
RecruitingNCT06519942SVT-DNPUpdated Sep 19, 2024

Muscle and Bone in Patients with Diabetes Mellitus and Neuropathy

An observational study in Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy and Sarcopenia, sponsored by University Hospital, Ghent. Recruiting at 1 site in Belgium. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by University Hospital, Ghent · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
145
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium — 13 open to participants now, 19 under way, 5 of them phase 3. Diabetes Mellitus, Type 2 · Belgium.

Planned enrollment
15th of 18
145 · median 759
Started
2023
with 4 others
Observational
18 of 149
6 open now
Primary completion
2025-11
later than 0 of 18 live
Registered
138th of 149
by date

Among the 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium, this one is the 15th largest by planned enrollment of the 18 observational ones that give a count, is one of 5 that started in 2023, is one of 18 observational ones, reaches primary completion later than 0 of the 18 other live ones, and was the 138th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

13 of the 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate muscle fiber type composition in people with type 2 diabetes mellitus (T2DM) with a common complication of T2DM: diabetic peripheral neuropathy (DNP), specifically diabetic sensorimotor polyneuropathy. Researchers will also look into factors related to DNP: inflammation, the use of energy in the cell, nerve function and the tiny blood vessels in the muscle.

The main question it aims to answer is: Are there differences in muscle fiber type composition between persons with T2DM with and without DNP, in comparison to sex and age-matched healthy peers?

Participants will partake in the following tests:

  • electromyoneurography (EMNG): evaluation of nerve function, damage and repair; for diagnosis of DNP or other diseases of the nerves
  • blood analysis: researchers will measure insulin, blood sugar, lipid profile, inflammation
  • muscle biopsy in the calf (m. gastrocnemius): a doctor will take a small sample of muscle to evaluate the muscle shape and structure
  • mechanography: patients will perform functional tests (e.g. standing up from a chair), researchers will evaluate maximal power and maximal force of the muscles by jumping tests
  • questionnaires: on food intake, physical activity, smoking history, alcohol use, medical history
  • measurement of height, weight, and the comparison of the hip and waist circumference
  • peripheral Quantitative Computed Tomography (pQCT): scan of the calf for muscle density and bone density
  • electrocardiography (ECG): evaluation of electrical signals of the heart

Researchers will compare (1) patients with T2DM with DNP, (2) patients with T2DM without DNP, and (3) healthy persons to see if there are differences in muscle fiber type composition

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Diabetic Peripheral Neuropathy
  • Sarcopenia
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Participants will be recruited through the Ghent University Hospital, diabetes educators and podologists.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants:

  • Between 40-70 years of age
  • between 18,5 - 35 kg/m2

Persons with T2DM:

  • More than 10-year clinical diagnosis of T2DM

Exclusion criteria

Exclusion Criteria:

All participants:

  • Possible other causes of nerve impairment (vitamin B12 deficiency, excessive alcohol consumption, chemotherapy)
  • Immobilisation (1) > 3 months in past history or (2) > 4 weeks in past 6 months
  • Chronic conditions affecting the vital organs ( (NYHA) 3/4, Global Initiative for Obstructive Lung Disease (GOLD) 3/4, cystic fibrosis)
  • Hypogonadism
  • Inflammatory joint or intestinal diseases
  • Chronic muscle diseases
  • Active
  • Malnutrition disease, eating disorder or bariatric surgery
  • Medication use (anticoagulants, , anti-androgen or anti-estrogen treatment) persons with T2DM:
  • Insufficient control of diabetes ( >9%)

Healthy controls:

  • Fasting glucose > 100 mg/dl
  • HbA1c > 5.7 %
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
145 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • T2DM DNP+

    type 2 diabetes with diabetic neuropathy

    Diagnostic Test: Blood sampling · Diagnostic Test: Electromyoneurography (EMNG) · Procedure: Muscle biopsy · Radiation: Quantitative peripheral computed tomography (qPCT) · Device: Mechanography · Diagnostic Test: Electrocardiography (ECG) · Other: Questionnaires · Other: Anthropometry

  • T2DM DNP-

    type 2 diabetes without diabetic neuropathy

    Diagnostic Test: Blood sampling · Diagnostic Test: Electromyoneurography (EMNG) · Procedure: Muscle biopsy · Radiation: Quantitative peripheral computed tomography (qPCT) · Device: Mechanography · Diagnostic Test: Electrocardiography (ECG) · Other: Questionnaires · Other: Anthropometry

  • HC

    healthy controls

    Diagnostic Test: Blood sampling · Diagnostic Test: Electromyoneurography (EMNG) · Procedure: Muscle biopsy · Radiation: Quantitative peripheral computed tomography (qPCT) · Device: Mechanography · Diagnostic Test: Electrocardiography (ECG) · Other: Questionnaires · Other: Anthropometry

Interventions

  • Diagnostic testBlood sampling

    Fasting blood samples will be obtained.

  • Diagnostic testElectromyoneurography (EMNG)

    Nerve conduction of sensory and motor nerves of the upper and lower limb will be performed, including F- and H-waves. Needle EMNG of the m. tibialis anterior, m. gastrocnemius (medial head), m. tensor fascia lata and m. gluteus maximus) will be performed.

  • ProcedureMuscle biopsy

    Muscle biopsy of the m. gastrocnemius will be performed under local anesthesia using the modified Bergström technique.

  • RadiationQuantitative peripheral computed tomography (qPCT)

    A qPCT scan of the calf will be performed.

  • DeviceMechanography

    Single two leg jump, multiple one leg hopping, chair rise and sit to stand tests will be performed.

  • Diagnostic testElectrocardiography (ECG)

    A 15-minute resting ECG will be performed.

  • OtherQuestionnaires

    Questionnaires will be performed to collect information on medical background (drug use, comorbidities, symptoms of peripheral neuropathy, ...) and lifestyle factors (ethyl consumption, food intake, physical activity, smoking).

  • OtherAnthropometry

    Length and hip:waist ratio will be measured. Furthermore, body weight and composition will be determined by bio-impedance measurement. Systolic and diastolic blood pressure (mean of 3 times) will be evaluated.

06

What researchers measure

Primary outcomes

  1. Differences in muscle fiber type composition in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Differences in muscle fiber type distribution, percentage and cross-sectional area will be evaluated through myosin heavy chain (MHC) immunostaining of the muscle specimen.

    Time frame: At enrollment

Secondary outcomes

  1. Differences in nerve conduction velocity in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls

    Nerve conduction velocity will be examined through EMNG examination to examine neuromotor function

    Time frame: At enrollment

  2. Differences in capillarization in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Capillarization will be examined through histological examination of the muscle specimen using Ulex europaeus I (UEA-I) staining.

    Time frame: At enrollment

  3. Differences in electron microscopic properties assessing mitochondrial function in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls

    Mitochondrial function will be examined through electron microscopy of the muscle specimen.

    Time frame: At enrollment

  4. Differences in maximal force in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Maximal force will be evaluated using mechanography through multiple one leg hopping.

    Time frame: At enrollment

  5. Differences in maximal power in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Maximal power will be evaluated using mechanography through the single two leg jump.

    Time frame: At enrollment

  6. Differences in functional muscle strength in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Functional strength will be examined using mechanography through the chair rising test and heel rise test.

    Time frame: At enrollment

  7. Differences in physical activity levels in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Differences in the lifestyle factor physical activity will be examined through the International Physical Activity Questionnaire (IPAQ) - Long Form).

    Time frame: At enrollment

  8. Differences in food intake in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Differences in the lifestyle factor food intake will be examined through a food frequency questionnaire.

    Time frame: At enrollment

  9. Differences in lifestyle factors in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Differences in lifestyle factors smoking and ethyl consumption will be examined through non-official questionnaires.

    Time frame: At enrollment

  10. Differences in muscle density in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Differences in muscle density will be evaluated through pQCT of the calf.

    Time frame: At enrollment

  11. Differences in bone density in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Differences in bone density will be evaluated through pQCT of the calf.

    Time frame: At enrollment

Other outcomes

  1. Differences in heart rate variability in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Heart rate variability will be examined through a 15-minute resting ECG.

    Time frame: At enrollment

  2. Differences in interleukin 6 (IL-6) concentration in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Differences in inflammation will be evaluated through blood analysis of IL-6.

    Time frame: At enrollment

  3. Differences in tumor necrosis factor alpha (TNFα) concentration in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Differences in inflammation will be evaluated through blood analysis of TNFα.

    Time frame: At enrollment

  4. Differences in C-reactive protein (CRP) concentration in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Differences in inflammation will be evaluated through blood analysis of CRP.

    Time frame: At enrollment

  5. Differences in mononuclear cell numbers in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Differences in inflammation will be evaluated through flow cytometry to assess mononuclear cell numbers.

    Time frame: At enrollment

  6. Differences in protein concentrations for AMPK and PGC-1α in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls

    Differences in protein concentrations for 5' adenosine monophosphate-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1α) will be examined using western blotting (on the muscle sample)

    Time frame: At enrollment

  7. Differences in citrate synthase activity in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls

    Citrate synthase activity will be examined using an activity assay (on the muscle sample).

    Time frame: At enrollment

  8. Differences in succinate dehydrogenase B (SDHB) expression in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls

    SDHB expression will be examined through immunohistochemical staining for SDHB of the muscle specimen.

    Time frame: At enrollment

  9. Differences in vascular endothelial growth factor (VEGF) concentrations in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

    Vascular endothelial growth factor concentrations will be examined through blood analysis.

    Time frame: At enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — After publication, anonymous individual participant data can be made available to other researchers upon request.

Supporting information: Study protocol, Informed consent form

Time frame: After publication

Access criteria: Upon request to corresponding author

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Nov 2025, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2024
First posted
Jul 25, 2024
StartActual
Dec 12, 2023
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2025
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06519942
Collaborators
University Ghent
Responsible party
Sponsor
First posted
Jul 25, 2024
Start date
Dec 12, 2023
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Sep 19, 2024

Study contacts

Cato Van De Looverbosch
Contact
cato.vandelooverbosch@ugent.be
0479922969
Bruno Lapauw
principal investigator · University Hospital, Ghent

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion